Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and Sysnav Healthcare are collaborating to develop industry standard outcome measurements in diseases linked with movement impairments and also design the next generation of wearable technology based on Sysnav’s technology.

Sysnav said it has developed medical grade wearables based on magneto-inertial technology for 3D movement reconstruction. This enables precise movement tracking without GPS, thus protecting patient privacy while enabling indoor monitoring.

Patients living with a neuromuscular disorder often have movement restrictions, thus objective measurements of a patient’s change in motor function can help doctors prescribe appropriate therapy, according to the companies.

Sysnav and Roche said they have expanded their collaboration across multiple programs to develop digital goals that will monitor disease progression, support clinical trials and serve as regulatory approved standards of outcome measurement.

“Bringing together Sysnav’s digital health technology and Roche’s expertise in neuroscience drug development and personalised healthcare will enable us to have a truly meaningful impact on patients with motor impairments,” said Damien Eggenspieler, Sysnav Program director.

Sysnav added that it has already secured the first-ever qualification of a digital endpoint (SV95c) with the European Medicines Agency for Duchenne’s Muscular Dystrophy, having worked with academic collaborators, patients associations and Roche.

The partnership will also develop the next generation wearable technology to promote personalized healthcare.